It never finishes, often because insufficient participants were recruited, or
It is never published, due to poor design or an inadequate analysis plan, or
It is published but focuses on a question other than the original research question, or
It is published only after many years’ delay, or
It is published promptly and stakeholders must accept criticism for wasted money and resources.
The chance that a study ends informatively increases when:
References
Zarin DA, Goodman SN, Kimmelman J. Harms from uninformative clinical trials. Jama. 2019 Sep 3;322(9):813-4.
Hutchinson, Nora, et al. “The proportion of randomized controlled trials that inform clinical practice.” Elife 11 (2022): e79491.
If you would like to cite the tool alone, you can cite:
Wood TA and McNair D. Clinical Trial Risk Tool: software application using natural language processing to identify the risk of trial uninformativeness. Gates Open Res 2023, 7:56 doi: 10.12688/gatesopenres.14416.1.
A BibTeX entry for LaTeX users is
@article{Wood_2023, doi = {10.12688/gatesopenres.14416.1}, url = {https://doi.org/10.12688%2Fgatesopenres.14416.1}, year = 2023, month = {apr}, publisher = {F1000 Research Ltd}, volume = {7}, pages = {56}, author = {Thomas A Wood and Douglas McNair}, title = {Clinical Trial Risk Tool: software application using natural language processing to identify the risk of trial uninformativeness}, journal = {Gates Open Research} }
Site maintained by Fast Data Science Ltd | Privacy Policy